低剂量阿司匹林新使用者胃溃疡和十二指肠溃疡风险显著增加:两项新使用者设计大型队列研究结果
在德国ESTHER研究(N=7737)和英国生物样本库(N=213598)中,采用多变量Cox回归分析低剂量阿司匹林与胃溃疡、十二指肠溃疡发病的关系。新使用者设计下,英国生物样本库胃溃疡和十二指肠溃疡的风险比分别为1.82和1.66,ESTHER研究分别为2.83和3.89;而现患使用者设计中关联不显著或较弱。结论认为低剂量阿司匹林是胃溃疡和十二指肠溃疡的独立危险因素。
要点
- 新使用者设计中低剂量阿司匹林与胃溃疡、十二指肠溃疡风险显著相关。
- 现患使用者设计中两队列胃溃疡关联均不显著,十二指肠溃疡关联弱或不显著。
- 开始低剂量阿司匹林治疗时需权衡风险与获益,并监测胃肠道不良反应症状。
核心结论
- 低剂量阿司匹林是胃溃疡和十二指肠溃疡的独立危险因素。
- 现患使用者设计中关联不显著或较弱,新使用者设计中两队列关联强且具统计学显著性。
- 开始低剂量阿司匹林治疗时需权衡风险与获益,并监测治疗开始后的胃肠道不良反应症状。
研究设计与样本
- 德国ESTHER研究(N=7737)和英国生物样本库(N=213598)两项队列,随访超过10年。
- 采用多变量Cox回归模型,分别按现患使用者设计和新使用者设计分析。
主要发现
- 现患使用者设计中,两队列低剂量阿司匹林与胃溃疡均无显著关联。
- 现患使用者设计中,英国生物样本库低剂量阿司匹林与十二指肠溃疡呈弱但具统计学显著关联(风险比1.27,95%CI 1.07-1.51),ESTHER研究无显著关联(1.33,95%CI 0.54-3.29)。
- 新使用者设计中,英国生物样本库胃溃疡风险比1.82(95%CI 1.58-2.11),十二指肠溃疡风险比1.66(95%CI 1.36-2.04)。
- 新使用者设计中,ESTHER研究胃溃疡风险比2.83(95%CI 1.40-5.71),十二指肠溃疡风险比3.89(95%CI 1.46-10.42)。
临床怎么用
- 开始低剂量阿司匹林治疗时需权衡风险与获益,并监测治疗开始后的胃肠道不良反应症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-dose aspirin is a risk factor for peptic ulcer disease but previous, population-based cohort studies may have underestimated the low-dose aspirin risk because they did not use a new-user design. Gastrointestinal bleeding occurs more frequently early after initiation of low-dose aspirin therapy than in later years. AIM: To assess the associations of low-dose aspirin with gastric and duodenal ulcer incidence in prevalent- and new-user design. METHODS: Multivariate Cox regression models in the German ESTHER study (N = 7737) and the UK Biobank (N = 213,598) with more than 10 years of follow-up. RESULTS: In the prevalent-user design, there was no significant association between low-dose aspirin and gastric ulcer observed in both cohorts. Furthermore, low-dose aspirin was weakly, statistically significantly associated with prevalent duodenal ulcer in the UK Biobank (hazard ratio [95% confidence interval]: 1.27 [1.07-1.51]) but not in the ESTHER study (1.33 [0.54-3.29]). When restricting the exposure to only new users, the hazard ratios for incident gastric and duodenal ulcer disease were 1.82 [1.58-2.11] and 1.66 [1.36-2.04] in the UK Biobank, respectively, and 2.83 [1.40-5.71] and 3.89 [1.46-10.42] in the ESTHER study, respectively. CONCLUSIONS: This study shows that low-dose aspirin is an independent risk factor for both gastric and duodenal ulcers. The associations were not significant or weak in the prevalent-user design and strong and statistically significant in the new-user design in both cohorts. Thus, it is important to weigh risks against benefits when low-dose aspirin treatment shall be initiated and to monitor adverse gastrointestinal symptoms after the start of low-dose aspirin therapy.
引用
- Nguyen TNM, Sha S, Chen LJ, et al. Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design. Aliment Pharmacol Ther. 2022. PMID: 35621052. doi:10.1111/apt.17050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。